CARDIFF ONCOLOGY, INC. Amortization of Debt Issuance Costs and Discounts
CARDIFF ONCOLOGY, INC. (CRDF) reported Amortization of Debt Issuance Costs and Discounts of $2.35 million for the 176-month period ending 2014-03-31, per its 10-Q filed 2014-05-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2014-05-12
- 2014-03-31: .
- 2013-12-31: .
- 2013-09-30: .
- 2013-06-30: .
| Period end | Amortization of Debt Issuance Costs and Discounts 152 month | Amortization of Debt Issuance Costs and Discounts 155 month | Amortization of Debt Issuance Costs and Discounts 158 month | Amortization of Debt Issuance Costs and Discounts 161 month | Amortization of Debt Issuance Costs and Discounts 164 month | Amortization of Debt Issuance Costs and Discounts 167 month | Amortization of Debt Issuance Costs and Discounts 170 month | Amortization of Debt Issuance Costs and Discounts 173 month | Amortization of Debt Issuance Costs and Discounts 176 month |
|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $2.35M 10-Q · filed 2014-05-12 | ||||||||
| 2013-12-31 | $2.35M 10-K · filed 2014-03-17 | ||||||||
| 2013-09-30 | $2.35M 10-Q · filed 2013-11-14 | ||||||||
| 2013-06-30 | $2.35M 10-Q · filed 2013-08-14 | ||||||||
| 2013-03-31 | $2.35M 10-Q · filed 2013-05-14 | ||||||||
| 2012-12-31 | $2.35M 10-K · filed 2013-04-01 | ||||||||
| 2012-09-30 | $2.35M 10-Q · filed 2012-11-14 | ||||||||
| 2012-06-30 | $2.35M 10-Q · filed 2012-08-14 | ||||||||
| 2012-03-31 | $2.35M 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |